Anebulo Pharmaceuticals, Inc.
ANEB
$2.30
-$0.01-0.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.48M | -7.69M | -7.67M | -7.92M | -8.20M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 382.00K | 424.30K | 238.80K | 210.90K | 151.20K |
| Total Other Non-Cash Items | 1.45M | 1.28M | 1.18M | 835.00K | 758.90K |
| Change in Net Operating Assets | 306.20K | -768.70K | -397.70K | -178.40K | -799.30K |
| Cash from Operations | -6.35M | -6.75M | -6.65M | -7.05M | -8.09M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.00M | 15.00M | 15.00M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -116.70K | -116.70K | 0.00 | -62.40K | -62.40K |
| Cash from Financing | 14.88M | 14.88M | 15.00M | -62.40K | -62.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.53M | 8.13M | 8.35M | -7.12M | -8.15M |